Assumpció L. P.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase III Randomized Trial of Trastuzumab, Alpelisib, and Fulvestrant Versus Trastuzumab and Chemotherapy in PIK3CA-Mutated HER2+ Advanced Breast Cancer
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
- Phase 3 Multicenter Randomized Study of Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in High-Risk HER2-Positive Breast Cancer with Residual Disease
Data & Insights
Has run more than one trial at 180 of 426 partner sites.
Specializations
HER2-Related Breast Cancer
Focused on investigating therapeutic approaches for HER2-positive breast cancer, particularly in high-risk patients and those with residual disease following neoadjuvant therapy. The investigator explores treatment options including trastuzumab-based combinations and novel targeted therapies.
- Advanced HER2+ Disease Management
- Post-Neoadjuvant Treatment Strategies
- PIK3CA Mutated HER2+ Cancer
Hormone Receptor-Positive Breast Cancer
Specializes in developing treatment strategies for hormone receptor-positive breast cancer, with particular emphasis on endocrine therapy combinations and targeted treatments. The investigator studies alternative approaches to conventional chemotherapy, especially in older patient populations.
- Endocrine Therapy Optimization
- Age-Specific Treatment Approaches
- Risk-Adapted Therapy Selection
Triple-Negative and Advanced Disease
Conducts research in triple-negative breast cancer treatment modalities and investigates novel therapeutic approaches for advanced disease states. The investigator evaluates immunotherapy combinations and innovative targeted treatments for high-risk patient populations.
- Neoadjuvant Treatment Protocols
- Immunotherapy Applications
- High-Risk Disease Management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.